The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Research Report 2025

Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1718644

No of Pages : 95

Ask Your Query
Synopsis
The global Non-Peptide Drugs of Angiotensin II Receptor Antagonist market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Non-Peptide Drugs of Angiotensin II Receptor Antagonist, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Peptide Drugs of Angiotensin II Receptor Antagonist.
Report Scope
The Non-Peptide Drugs of Angiotensin II Receptor Antagonist market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Peptide Drugs of Angiotensin II Receptor Antagonist market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Peptide Drugs of Angiotensin II Receptor Antagonist companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis
Merck
AstraZeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals 
Sun Pharmaceutical
Mylan
Alembic Pharmaceuticals
Lupin
Aurobindo Pharma
Amneal Pharmaceuticals
Boehringer Ingelheim
Segment by Type
Valsartan
Irbesartan
Candesartan Cilexetil
Eprosartan
Irbesartan
Telmisartan
losartan
Olmesartan Medoxomil
Allisartan isoproxil
Segment by Application
High Blood Pressure
Congestive Heart Failure
Left Ventricular Hypertrophy
Atherosclerosis
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Peptide Drugs of Angiotensin II Receptor Antagonist companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Valsartan
1.2.3 Irbesartan
1.2.4 Candesartan Cilexetil
1.2.5 Eprosartan
1.2.6 Irbesartan
1.2.7 Telmisartan
1.2.8 losartan
1.2.9 Olmesartan Medoxomil
1.2.10 Allisartan isoproxil
1.3 Market by Application
1.3.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 High Blood Pressure
1.3.3 Congestive Heart Failure
1.3.4 Left Ventricular Hypertrophy
1.3.5 Atherosclerosis
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Perspective (2019-2030)
2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Growth Trends by Region
2.2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Size by Region (2019-2024)
2.2.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Region (2025-2030)
2.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Dynamics
2.3.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Industry Trends
2.3.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Drivers
2.3.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Challenges
2.3.4 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Revenue
3.1.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Revenue (2019-2024)
3.1.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Players (2019-2024)
3.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue
3.4 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio
3.4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2023
3.5 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players Head office and Area Served
3.6 Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Solution and Service
3.7 Date of Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Breakdown Data by Type
4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Size by Type (2019-2024)
4.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Type (2025-2030)
5 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Breakdown Data by Application
5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Size by Application (2019-2024)
5.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2019-2030)
6.2 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2019-2024)
6.4 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2019-2030)
7.2 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2019-2024)
7.4 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2019-2030)
8.2 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2019-2024)
8.4 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2019-2030)
9.2 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2019-2024)
9.4 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2019-2030)
10.2 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2019-2024)
10.4 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.1.4 Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.2.4 Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.3.4 Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.3.5 Merck Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.4.4 AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.4.5 AstraZeneca Recent Development
11.5 Jhonson and Johnson
11.5.1 Jhonson and Johnson Company Detail
11.5.2 Jhonson and Johnson Business Overview
11.5.3 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.5.4 Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.5.5 Jhonson and Johnson Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Detail
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.6.4 Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.6.5 Eli Lilly Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.7.4 Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.7.5 Sanofi Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.8.4 Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Bayer
11.9.1 Bayer Company Detail
11.9.2 Bayer Business Overview
11.9.3 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.9.4 Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.9.5 Bayer Recent Development
11.10 GSK
11.10.1 GSK Company Detail
11.10.2 GSK Business Overview
11.10.3 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.10.4 GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.10.5 GSK Recent Development
11.11 Teva Pharmaceutical
11.11.1 Teva Pharmaceutical Company Detail
11.11.2 Teva Pharmaceutical Business Overview
11.11.3 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.11.4 Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.11.5 Teva Pharmaceutical Recent Development
11.12 Shenzhen Salubris Pharmaceuticals 
11.12.1 Shenzhen Salubris Pharmaceuticals  Company Detail
11.12.2 Shenzhen Salubris Pharmaceuticals  Business Overview
11.12.3 Shenzhen Salubris Pharmaceuticals  Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.12.4 Shenzhen Salubris Pharmaceuticals  Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.12.5 Shenzhen Salubris Pharmaceuticals  Recent Development
11.13 Sun Pharmaceutical
11.13.1 Sun Pharmaceutical Company Detail
11.13.2 Sun Pharmaceutical Business Overview
11.13.3 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.13.4 Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.13.5 Sun Pharmaceutical Recent Development
11.14 Mylan
11.14.1 Mylan Company Detail
11.14.2 Mylan Business Overview
11.14.3 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.14.4 Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.14.5 Mylan Recent Development
11.15 Alembic Pharmaceuticals
11.15.1 Alembic Pharmaceuticals Company Detail
11.15.2 Alembic Pharmaceuticals Business Overview
11.15.3 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.15.4 Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.15.5 Alembic Pharmaceuticals Recent Development
11.16 Lupin
11.16.1 Lupin Company Detail
11.16.2 Lupin Business Overview
11.16.3 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.16.4 Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.16.5 Lupin Recent Development
11.17 Aurobindo Pharma
11.17.1 Aurobindo Pharma Company Detail
11.17.2 Aurobindo Pharma Business Overview
11.17.3 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.17.4 Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.17.5 Aurobindo Pharma Recent Development
11.18 Amneal Pharmaceuticals
11.18.1 Amneal Pharmaceuticals Company Detail
11.18.2 Amneal Pharmaceuticals Business Overview
11.18.3 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.18.4 Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.18.5 Amneal Pharmaceuticals Recent Development
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Detail
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.19.4 Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
11.19.5 Boehringer Ingelheim Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Valsartan
Table 3. Key Players of Irbesartan
Table 4. Key Players of Candesartan Cilexetil
Table 5. Key Players of Eprosartan
Table 6. Key Players of Irbesartan
Table 7. Key Players of Telmisartan
Table 8. Key Players of losartan
Table 9. Key Players of Olmesartan Medoxomil
Table 10. Key Players of Allisartan isoproxil
Table 11. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 12. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 13. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2019-2024) & (US$ Million)
Table 14. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Region (2019-2024)
Table 15. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 16. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Region (2025-2030)
Table 17. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Trends
Table 18. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Drivers
Table 19. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Challenges
Table 20. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Restraints
Table 21. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Players (2019-2024) & (US$ Million)
Table 22. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Players (2019-2024)
Table 23. Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2023)
Table 24. Ranking of Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Companies by Revenue (US$ Million) in 2023
Table 25. Global 5 Largest Players Market Share by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (CR5 and HHI) & (2019-2024)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Solution and Service
Table 28. Date of Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2019-2024) & (US$ Million)
Table 31. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Type (2019-2024)
Table 32. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 33. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Type (2025-2030)
Table 34. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2019-2024) & (US$ Million)
Table 35. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Application (2019-2024)
Table 36. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 37. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Application (2025-2030)
Table 38. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2019-2024) & (US$ Million)
Table 40. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2025-2030) & (US$ Million)
Table 41. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2019-2024) & (US$ Million)
Table 43. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2025-2030) & (US$ Million)
Table 44. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 45. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2019-2024) & (US$ Million)
Table 46. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2025-2030) & (US$ Million)
Table 47. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2019-2024) & (US$ Million)
Table 49. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2025-2030) & (US$ Million)
Table 50. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 51. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2019-2024) & (US$ Million)
Table 52. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2025-2030) & (US$ Million)
Table 53. Pfizer Company Detail
Table 54. Pfizer Business Overview
Table 55. Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 56. Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 57. Pfizer Recent Development
Table 58. Novartis Company Detail
Table 59. Novartis Business Overview
Table 60. Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 61. Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 62. Novartis Recent Development
Table 63. Merck Company Detail
Table 64. Merck Business Overview
Table 65. Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 66. Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 67. Merck Recent Development
Table 68. AstraZeneca Company Detail
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 71. AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 72. AstraZeneca Recent Development
Table 73. Jhonson and Johnson Company Detail
Table 74. Jhonson and Johnson Business Overview
Table 75. Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 76. Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 77. Jhonson and Johnson Recent Development
Table 78. Eli Lilly Company Detail
Table 79. Eli Lilly Business Overview
Table 80. Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 81. Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 82. Eli Lilly Recent Development
Table 83. Sanofi Company Detail
Table 84. Sanofi Business Overview
Table 85. Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 86. Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 87. Sanofi Recent Development
Table 88. Bristol-Myers Squibb Company Detail
Table 89. Bristol-Myers Squibb Business Overview
Table 90. Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 91. Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 92. Bristol-Myers Squibb Recent Development
Table 93. Bayer Company Detail
Table 94. Bayer Business Overview
Table 95. Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 96. Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 97. Bayer Recent Development
Table 98. GSK Company Detail
Table 99. GSK Business Overview
Table 100. GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 101. GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 102. GSK Recent Development
Table 103. Teva Pharmaceutical Company Detail
Table 104. Teva Pharmaceutical Business Overview
Table 105. Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 106. Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 107. Teva Pharmaceutical Recent Development
Table 108. Shenzhen Salubris Pharmaceuticals  Company Detail
Table 109. Shenzhen Salubris Pharmaceuticals  Business Overview
Table 110. Shenzhen Salubris Pharmaceuticals  Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 111. Shenzhen Salubris Pharmaceuticals  Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 112. Shenzhen Salubris Pharmaceuticals  Recent Development
Table 113. Sun Pharmaceutical Company Detail
Table 114. Sun Pharmaceutical Business Overview
Table 115. Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 116. Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 117. Sun Pharmaceutical Recent Development
Table 118. Mylan Company Detail
Table 119. Mylan Business Overview
Table 120. Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 121. Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 122. Mylan Recent Development
Table 123. Alembic Pharmaceuticals Company Detail
Table 124. Alembic Pharmaceuticals Business Overview
Table 125. Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 126. Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 127. Alembic Pharmaceuticals Recent Development
Table 128. Lupin Company Detail
Table 129. Lupin Business Overview
Table 130. Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 131. Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 132. Lupin Recent Development
Table 133. Aurobindo Pharma Company Detail
Table 134. Aurobindo Pharma Business Overview
Table 135. Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 136. Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 137. Aurobindo Pharma Recent Development
Table 138. Amneal Pharmaceuticals Company Detail
Table 139. Amneal Pharmaceuticals Business Overview
Table 140. Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 141. Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 142. Amneal Pharmaceuticals Recent Development
Table 143. Boehringer Ingelheim Company Detail
Table 144. Boehringer Ingelheim Business Overview
Table 145. Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 146. Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024) & (US$ Million)
Table 147. Boehringer Ingelheim Recent Development
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type: 2023 VS 2030
Figure 3. Valsartan Features
Figure 4. Irbesartan Features
Figure 5. Candesartan Cilexetil Features
Figure 6. Eprosartan Features
Figure 7. Irbesartan Features
Figure 8. Telmisartan Features
Figure 9. losartan Features
Figure 10. Olmesartan Medoxomil Features
Figure 11. Allisartan isoproxil Features
Figure 12. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 13. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application: 2023 VS 2030
Figure 14. High Blood Pressure Case Studies
Figure 15. Congestive Heart Failure Case Studies
Figure 16. Left Ventricular Hypertrophy Case Studies
Figure 17. Atherosclerosis Case Studies
Figure 18. Others Case Studies
Figure 19. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Report Years Considered
Figure 20. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 21. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 22. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Region: 2023 VS 2030
Figure 23. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Players in 2023
Figure 24. Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2023)
Figure 25. The Top 10 and 5 Players Market Share by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2023
Figure 26. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Country (2019-2030)
Figure 28. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Canada Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Country (2019-2030)
Figure 32. Germany Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. France Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. U.K. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Italy Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Russia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Nordic Countries Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Region (2019-2030)
Figure 40. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. South Korea Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Australia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Country (2019-2030)
Figure 48. Mexico Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Brazil Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Country (2019-2030)
Figure 52. Turkey Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Pfizer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 55. Novartis Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 56. Merck Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 57. AstraZeneca Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 58. Jhonson and Johnson Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 59. Eli Lilly Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 60. Sanofi Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 62. Bayer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 63. GSK Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 64. Teva Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 65. Shenzhen Salubris Pharmaceuticals  Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 66. Sun Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 67. Mylan Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 68. Alembic Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 69. Lupin Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 70. Aurobindo Pharma Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 71. Amneal Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 72. Boehringer Ingelheim Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2019-2024)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock